Weed Killer Proves Beneficial For Rare Liver Disease

Article

WASHINGTON, DC-Parents of children born with tyrosinemia were warned that those inflicted with the hereditary disease have a 29% survival rate. The rare liver disease prevents the body from properly breaking down specific amino acids.

However, a rare solution may help fight the rare disease. Researchers at Sweden's Gothenberg University noticed a failed herbicide, produced by Zeneca Inc., broke down the same amino acid compounds. The drug Orfadin was created from the failed weed killer, and patented by a mall Nashville-based pharmaceutical company-Rare Disease Therapeutics.

Hereditary tyrosinemia type 1 causes progressive liver failure and liver cancer in young children. Yet in Orfadin studies, 89% of those inflicted lived four years or more. The drug blocks specific liver-destroying proteins. Previous treatments centered on no-protein diets, but were rarely successful.

The drug will cost $12,000 per year for infants, but Rare Disease Therapeutic vice president Bo Allen has said no child will be turned away from treatment.

The company received a special seven-year patent on the drug through an FDA program for rare diseases.

There are an estimated 100 children with the disease.

Information from www.msnbc.com

Related Videos
Andrea Flinchum, 2024 president of the Certification Board of Infection Control and Epidemiology, Inc (CBIC) explains the AL-CIP Certification at APIC24
Association for Professionals in Infection Control and Epidemiology  (Image credit: APIC)
Lila Price, CRCST, CER, CHL, the interim manager for HealthTrust Workforce Solutions; and Dannie O. Smith III, BSc, CSPDT, CRCST, CHL, CIS, CER, founder of Surgicaltrey, LLC, and a central processing educator for Valley Health System
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Related Content